";s:4:"text";s:5500:" In order to assess effectiveness and safety of trazodone, longer-term randomized controlled trials are needed, involving larger samples of participants with a wider variety of types and severities of dementia.The rationale for using trazodone is that it is a sedating atypical serotonergic antidepressant with a low rate of adverse effects and some behavioural and psychological symptoms in people with dementia (BPSD) are associated with serotonergic dysfunction. Functional serotonergic deficits may be related to the genesis of behavioural disturbances in dementia.To determine the clinical efficacy and safety of trazodone, for any type of behavioural or psychological cognition in people with dementia without an additional diagnosis of depression.The Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (CDCIG), The Cochrane Library, MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS were searched on 23 March 2008 using the terms: trazodone* OR beneficat OR desirel OR sideril OR trazodil OR trazalon. The rationale for using trazodone is that it is a sedating atypical serotonergic antidepressant with a low rate of adverse effects and some behavioural and psychological symptoms in people with dementia (BPSD) are associated with serotonergic dysfunction. In vitro and animal studies have suggested that trazodone, a licensed antidepressant, may protect against dementia. The use of antidepressants with hypnotic actions, such as trazodone, plays an important role in these cases. 2018 Dec;52:168-176. doi: 10.1016/j.sleep.2018.09.001. Scientific Electronic Library Online COVID-19 is an emerging, rapidly evolving situation. 2017 Aug 1;14(7-8):24-34. eCollection 2017 Jul-Aug.Dis Model Mech. It was not possible to pool the data. Approximately 85% of patients with SD used hypnosedative drugs. The parallel study also assessed activities of daily living and caregiver burden. Trazodone was the most commonly used drug among patients (N = 35), with an effectiveness of 65.7%. If you continue to use this site we will assume that you are happy with it. 2020 Jun 30;11:620. doi: 10.3389/fpsyt.2020.00620. doi: 10.1590/s0004-282x2011000100010. 2015 Jun;48(4):312-7. doi: 10.1007/s00391-015-0890-3. The aim of this study is to present a profile of the use of trazodone in demented patients with SD, as well as a review of trazodone hydrochloride in SD. received an overall rating of 6 out of 10 stars from 314 reviews. The conclusion is based on limited data from two small studies. Epub 2016 Dec 21.Einstein (Sao Paulo). J Clin Psychiatry. The incidence of dementia among trazodone users was higher than in matched antidepressant users (1.8 vs 1.1 dementia cases per 100 person-years) with a hazard ratio of 1.80 (95 percent confidence interval). Trazodone is a psychoactive compound with sedative and antidepressant properties, and with mixed serotonin agonist and antagonist effects. 2018 Oct-Dec;11(4):208-215. doi: 10.1016/j.rpsm.2016.11.003. Clipboard, Search History, and several other advanced features are temporarily unavailable. The results from this extension study have not been used in the analysis. Both trials examined global clinical state, behavioural disturbances and cognitive function. 2014 Mar 21;(3):CD009178. The studies were respectively of 16 and six weeks duration, using trazodone from 50 to 300 mg daily. Trazodone has been shown to be a good option for treatment of the elderly with dementia and associated SD. The rationale for using trazodone is that it is a sedating atypical serotonergic antidepressant with a low rate of adverse effects and some behavioural and psychological symptoms in people with dementia (BPSD) are associated with serotonergic dysfunction. The aim of this study is to present a profile of the use of trazodone in demented patients with SD, as well as a review of trazodone hydrochloride in SD. Epub 2015 May 9. Scientific Electronic Library Online 2015 Jul-Sep;13(3):430-4. doi: 10.1590/S1679-45082015RW3021.
The larger of the studies, conducted in 73 patients with Alzheimer’s disease, showed no beneficial effect of trazodone at all. Neuroleptic drugs are extensively prescribed to treat behavioural manifestations of dementia in spite of only modest efficacy and a high frequency of adverse effects. doi: 10.1002/14651858.CD009178.pub2.Kolla BP, Schneekloth TD, Biernacka JM, Frye MA, Mansukhani MP, Hall-Flavin DK, Karpyak VM, Loukianova LL, Lesnick TG, Mrazek D.Am J Addict. There is clearly a need for safer and more effective remedies. Sleep disorders (SD) in patients with dementia are very common in clinical practice. A variety of adverse effects were recorded with no significant differences between trazodone and placebo.There is insufficient evidence to recommend the use of trazodone as a treatment for behavioural and psychological manifestations of dementia.